首页> 外文OA文献 >Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

【2h】

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

机译：曲妥珠单抗和基于蒽环素的新辅助化疗对HER2阳性乳腺癌的疗效和心脏安全性：系统评价和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yu-Tuan Wu; Zhou Xu; Ke Zhang; Jiu-song Wu; Xin Li; Bilal Arshad; Ying-Cun Li; Zhong-Liang Wang; Hong-Yuan Li; Kai-Nan Wu; Ling-Quan Kong;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis [J] . Yu-Tuan Wu, Zhou Xu, Ke Zhang, Therapeutics and Clinical Risk Management . 2018,第2期

机译：曲妥珠单抗和蒽环类新辅助化疗同时治疗HER2阳性乳腺癌的疗效和心脏安全性：系统评价和荟萃分析
2. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials [J] . Journal of Cancer . 2018,第17期

机译：同时使用曲妥珠单抗和蒽环类新辅助化疗治疗HER2阳性乳腺癌的病理完全缓解（pCR）显着更高：来自随机对照试验的荟萃分析的证据
3. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials [J] . Journal of Cancer . 2018,第17期

机译：同时使用曲妥珠单抗和蒽环类新辅助化疗治疗HER2阳性乳腺癌的病理完全缓解（pCR）显着更高：来自随机对照试验的荟萃分析的证据
4. Clinical implications of HER-2 and p53 in taxane-based and anthracycline-based neoadjuvant chemotherapy in breast cancer [C] . World congress on breast diseases . 2008

机译：HER-2和P53在紫杉烷基和蒽环类新辅助化疗的乳腺癌中的临床意义
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis [O] . Yu-Tuan Wu, Zhou Xu, Ke Zhang, 2018

机译：曲妥珠单抗和蒽环类新辅助化疗同时治疗HER2阳性乳腺癌的疗效和心脏安全性：系统评价和荟萃分析
7. PCN22 EFFICACY AND CARDIAC SAFETY OF TRASTUZUMAB (T) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY-STAGE BREAST CANCER: A SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA) [O] . Botrel TEA, Clark O, Clark LGO, 2010

机译：曲妥珠单抗（T）在HER2阳性早期乳腺癌辅助治疗中的PCN22疗效和心脏安全性：系统评价（SR）和meta分析（MA）

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

著录项

引文网络

相似文献

相关主题

期刊订阅